Study of immune environment in operable stomach cancer
Part of Cancer clinical trials.
This study looks at how the immune system behaves in stomach or lower esophagus cancer before standard (planned) surgery. It may help researchers understand which immune features relate to outcomes and treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign consent for the study.
- You have confirmed stomach or lower esophagus (gastroesophageal junction) adenocarcinoma that has not spread to distant sites.
- Your cancer stage is IB, II, or III, and you will get standard chemotherapy and other neoadjuvant treatment before surgery.
- Your main tumor surgery must be done at Centre Léon Bérard.
- You have an archived tumor tissue sample from your diagnosis (a pathology block) with enough tumor cells for testing.
- Your general functioning (ECOG) is 0, 1, or 2, meaning you are able to do daily activities with limited help.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial collects and studies tumor and lymph node samples from people with gastric cancer who have had chemotherapy and surgery. The goal is to understand how cancer responds to treatment and to improve future care.
This trial looks at how medicines given around the time of stomach cancer surgery may change the “tumor microenvironment,” which is the biology around the tumor. It may help doctors better understand which perioperative treatments work best for locally advanced, operable stomach cancer.
This study looks at stomach (or stomach–esophagus junction) cancer tissue, treatment details, and patient-reported experiences to better predict how you may respond to standard chemotherapy. It may help personalize future treatment by identifying markers that connect your tumor environment and your expected outcomes.
This trial tests a combination of immunotherapy drugs (sintilimab, chemotherapy, and sometimes ipilimumab) given before surgery to shrink stomach or esophageal junction tumors, then continued after surgery. The goal is to improve survival in patients with resectable (removable) gastric or gastroesophageal junction cancer.
This trial studies blood-based biomarkers to help doctors choose the best individualized surgical treatment for gastroesophageal junction adenocarcinoma. If you qualify, you’ll get standard care plus additional testing to see whether the blood results can guide surgery more precisely.
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new GastroEsophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.